Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMPHNASDAQ:GLPGNASDAQ:GMTXNASDAQ:HRMY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$24.56-3.1%$24.77$22.64▼$53.96$1.19B0.77491,996 shs672,732 shsGLPGGalapagos$27.42-2.8%$27.23$22.36▼$31.23N/A0.07249,328 shs322,509 shsGMTXGemini Therapeutics$50.09+0.1%$46.96$1.16▼$14.10$2.17B-0.12189,291 shs321,187 shsHRMYHarmony Biosciences$31.89-1.8%$32.54$26.47▼$41.61$1.87B0.87628,036 shs662,452 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals-3.08%-4.88%+1.66%-13.18%-38.68%GLPGGalapagos-2.83%-4.66%-5.42%+6.20%+6.11%GMTXGemini Therapeutics0.00%-4.97%+0.02%-4.12%+15.04%HRMYHarmony Biosciences-1.82%-3.28%-7.57%-9.61%+10.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMPHAmphastar Pharmaceuticals4.2255 of 5 stars3.11.00.03.72.74.21.3GLPGGalapagos0.1938 of 5 stars0.82.00.00.01.30.00.6GMTXGemini TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AHRMYHarmony Biosciences4.7098 of 5 stars4.61.00.00.02.93.34.4Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPHAmphastar Pharmaceuticals 2.25Hold$32.3331.65% UpsideGLPGGalapagos 1.50Reduce$25.33-7.61% DownsideGMTXGemini Therapeutics 0.00N/AN/AN/AHRMYHarmony Biosciences 3.13Buy$53.6368.16% UpsideCurrent Analyst Ratings BreakdownLatest AMPH, HRMY, GLPG, and GMTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025HRMYHarmony BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$61.005/15/2025HRMYHarmony BiosciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$44.00 ➝ $48.005/13/2025HRMYHarmony BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/12/2025AMPHAmphastar PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$45.00 ➝ $30.005/8/2025AMPHAmphastar PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $35.005/6/2025HRMYHarmony BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$49.00 ➝ $49.004/28/2025HRMYHarmony BiosciencesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $48.004/10/2025AMPHAmphastar PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/8/2025HRMYHarmony BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.004/8/2025HRMYHarmony BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.003/21/2025AMPHAmphastar PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$36.00 ➝ $32.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPHAmphastar Pharmaceuticals$731.97M1.58$4.85 per share5.06$15.23 per share1.61GLPGGalapagos$298.31MN/A$0.71 per share38.87$47.57 per shareN/AGMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/AHRMYHarmony Biosciences$714.73M2.56$2.89 per share11.02$11.56 per share2.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPHAmphastar Pharmaceuticals$159.52M$2.768.907.476.6019.38%22.20%10.40%8/6/2025 (Estimated)GLPGGalapagos$80.16MN/A0.00N/AN/AN/AN/AN/A7/23/2025 (Estimated)GMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/AHRMYHarmony Biosciences$145.49M$2.6212.1710.250.4820.53%24.32%15.92%8/5/2025 (Estimated)Latest AMPH, HRMY, GLPG, and GMTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025HRMYHarmony Biosciences$0.59$0.78+$0.19$0.78$184.26 million$184.73 million4/23/2025Q1 2025GLPGGalapagos-$0.23-$2.47-$2.24-$2.45$72.22 million$97.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/AGLPGGalapagosN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPHAmphastar Pharmaceuticals0.802.952.02GLPGGalapagosN/A7.957.86GMTXGemini TherapeuticsN/A71.4971.49HRMYHarmony Biosciences0.223.673.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPHAmphastar Pharmaceuticals65.09%GLPGGalapagos32.46%GMTXGemini Therapeutics75.42%HRMYHarmony Biosciences86.23%Insider OwnershipCompanyInsider OwnershipAMPHAmphastar Pharmaceuticals27.50%GLPGGalapagos2.91%GMTXGemini Therapeutics12.90%HRMYHarmony Biosciences23.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPHAmphastar Pharmaceuticals2,02847.14 million34.18 millionOptionableGLPGGalapagos1,310N/AN/AOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableHRMYHarmony Biosciences20057.42 million43.87 millionOptionableAMPH, HRMY, GLPG, and GMTX HeadlinesRecent News About These CompaniesExchange Traded Concepts LLC Takes Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)June 20 at 3:52 AM | marketbeat.comHarmony Biosciences obtains favorable settlement in litigation over generic WakixJune 19 at 12:45 PM | drugstorenews.comSG Americas Securities LLC Has $1.17 Million Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)June 18 at 3:39 AM | marketbeat.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Sees Significant Increase in Short InterestJune 17, 2025 | marketbeat.comHarmony Biosciences (NASDAQ:HRMY) Trading Down 4.5% - Should You Sell?June 12, 2025 | marketbeat.com77,867 Shares in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Purchased by CX InstitutionalJune 12, 2025 | marketbeat.comMillennium Management LLC Has $218,000 Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)June 12, 2025 | marketbeat.comAnalysts Offer Predictions for HRMY FY2026 EarningsJune 12, 2025 | americanbankingnews.comCantor Fitzgerald Weighs in on HRMY FY2026 EarningsJune 11, 2025 | marketbeat.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by California State Teachers Retirement SystemJune 10, 2025 | marketbeat.comHarmony Biosciences Holdings, Inc. (HRMY): A Bull Case TheoryJune 9, 2025 | insidermonkey.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by Bridge City Capital LLCJune 9, 2025 | marketbeat.comHarmony Biosciences Holdings (HRMY) Shares Cross Below 200 DMAJune 7, 2025 | nasdaq.comHarmony Biosciences settles generic drug litigation, strengthens patentJune 6, 2025 | finance.yahoo.comHarmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA LitigationJune 5, 2025 | businesswire.comHennion & Walsh Asset Management Inc. Boosts Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)June 5, 2025 | marketbeat.comHarmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare ConferenceJune 4, 2025 | businesswire.comGAMMA Investing LLC Raises Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)June 4, 2025 | marketbeat.comSquarepoint Ops LLC Has $582,000 Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)June 4, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Invests $3.24 Million in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)June 3, 2025 | marketbeat.com4HRMY : Where Harmony Biosciences Hldgs Stands With AnalystsJune 2, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAMPH, HRMY, GLPG, and GMTX Company DescriptionsAmphastar Pharmaceuticals NASDAQ:AMPH$24.56 -0.78 (-3.08%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$24.56 0.00 (0.00%) As of 06/20/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Galapagos NASDAQ:GLPG$27.42 -0.80 (-2.83%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$27.42 0.00 (0.00%) As of 06/20/2025 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.Gemini Therapeutics NASDAQ:GMTX$50.09 +0.04 (+0.08%) As of 06/18/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.Harmony Biosciences NASDAQ:HRMY$31.89 -0.59 (-1.82%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$31.86 -0.03 (-0.09%) As of 06/20/2025 05:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
